Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposomes Combined With Sintilimab and Lenvatinib for Advanced Gastric Cancer
NCT06499610Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2024
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nanoliposomal irinotecan, sintilimab and lenvatinib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Intracranial Progression-Free Survival at 3 years. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecansintilimablenvatinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06499610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06499610.